Nieuws

GSK hoping to expand Arexvy usage in Japan
Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...
Investing.com6d
GSK’s Arexvy-vaccin onder EMA-evaluatie voor gebruik bij volwassenen
GSK blijft streven naar uitgebreide indicaties voor Arexvy in andere regio’s, waaronder de Verenigde Staten en Japan. Het vaccin is momenteel goedgekeurd in meer dan 60 landen voor personen van 60 ...
Berkeley posts 5% drop in annual earnings, GSK's RSV vaccine gets expanded use in Japan
Housebuilder Berkeley posted a 5% fall in annual earnings but said it was confident about the future against a backdrop of falling interest rates and government plans to ramp up supply using ...
Investing2mnd
GSK’s Arexvy nu aanbevolen voor risicogroep 50-59 jaar
en een indrukwekkende brutowinstmarge van 71,8%, maakte vandaag bekend dat het Amerikaanse Advisory Committee on Immunization Practices (ACIP) het gebruik van zijn respiratoir syncytieel virus (RSV) ...
Zacks.com on MSN3d
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...
Medical Dialogues5d
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
Investing2mnd
GSK’s Arexvy now recommended for adults 50-59 at risk
GSK’s Arexvy now recommended for adults 50-59 at risk ...
GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...
Investing2mnd
GSK’s Arexvy now recommended for adults 50-59 at risk
GSK’s Arexvy now recommended for adults 50-59 at risk Open in App Get 45% Off Sign In Free Sign Up ...